Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE BOLD: Bimekizumab vs risankizumab in adult psoriatic arthritis
jRCT2051240151Active, not recruiting
- Sponsor
- UCB
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Randomised, double-blind trial in psoriatic arthritis (PsA) comparing Bimekizumab arm with Risankizumab arm (2 arms). Primary endpoint: ACR50 response at Week 16. Started Nov 2024; status: active, not recruiting.
02
Drugs
bimekizumabrisankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2051240151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240151.